Cargando…

Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making

INTRODUCTION: Access and funding for newly approved treatments for non-small cell lung cancer (NSCLC) are often dependent on Health Technology Assessment (HTA) involving cost-effectiveness analysis. Whilst methods used by HTA agencies share many similarities, final decisions may differ. This may be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Jason, Stainthorpe, Angela, Jones, Beverley, Jacob, Ian, Hertel, Nadine, Diaz, Jose, Yuan, Yong, Borrill, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611140/ https://www.ncbi.nlm.nih.gov/pubmed/34216002 http://dx.doi.org/10.1007/s41669-021-00279-2

Ejemplares similares

HTA decision-making for drugs for rare diseases: comparison of processes across countries
por: Stafinski, Tania, et al.
Publicado: (2022)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

PNS173 Impact of COVID-19 on HTA Bodies and Pharmaceutical Company Pricing and Market Access Activities
por: Thomas, M., et al.
Publicado: (2020)

HTA Metro Map: a patient centred model for optimizing the decision making process
por: Chiumente, Marco, et al.
Publicado: (2019)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Worldwide HTA access to ICER's cost-effectiveness models
Publicado: (2020)

Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
por: Yuba, Tania Yuka, et al.
Publicado: (2018)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

POSC254 The Impact of COVID-19 on European HTA Decisions
por: Watson, C, et al.
Publicado: (2022)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

Evaluating facts and facting evaluations: On the fact‐value relationship in HTA
por: Hofmann, Bjørn, et al.
Publicado: (2018)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

The Role of Risk Aversion in Non-Conscious Decision Making
por: Wang, Shuo, et al.
Publicado: (2012)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA)
por: Brettschneider, Christian, et al.
Publicado: (2011)

PIN62 Recognising the broader value of vaccines in HTA: ready for prime time?
por: Brassel, S., et al.
Publicado: (2021)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

Pricing, management and decision-making of financial markets with artificial intelligence: introduction to the issue
por: Xiao, Feng, et al.
Publicado: (2021)

Assessing the potential of HTA to inform resource allocation decisions in low-income settings: The case of Malawi
por: Ramponi, Francesco, et al.
Publicado: (2022)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Ethics in HTA: Examining the "Need for Expansion"
por: Abrishami, Payam, et al.
Publicado: (2017)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

Market access and value-based pricing of digital health applications in Germany
por: Gensorowsky, Daniel, et al.
Publicado: (2022)

Price Decision-Making in Dual-Channel Healthcare Services Supply Chain Considering the Channel Acceptance, Price Ceiling, and Public Welfare
por: Ma, Yanbo, et al.
Publicado: (2022)

Feasibility and attractiveness of indication value-based pricing in key EU countries
por: Flume, Mathias, et al.
Publicado: (2016)

The impact of price transparency of bundled vacation packages on travel decision making: An experimental study
por: Bai, Shizhen, et al.
Publicado: (2022)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

Accessing Artificial Intelligence for Clinical Decision-Making
por: Giordano, Chris, et al.
Publicado: (2021)

The price of your soul: neural evidence for the non-utilitarian representation of sacred values
por: Berns, Gregory S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tfgrh7n9l1g3tdgh0si3frf479